This report presents a structured and objective analysis of the global Intravenous Immunoglobulin Market growth. With a focus on historical trends, current developments, and future projections, it offers a data-rich foundation for decision-makers, industry participants, and investors. The report includes both macro and micro-level insights, enabling readers to grasp key dynamics across segments, regions, and product categories.
Market Size and Forecast
Current Market Size:
Future Market Size:
CAGR:
Market Overview
This growth is calculated based on observed trends, actual industry performance, and current developments in product usage and adoption. The study takes into account the challenges faced by key players and the general market structure, while avoiding speculative interpretations. It focuses on providing a clear picture of market performance across different regions and segments.
This report supports strategic planning by delivering verified data, cross-segment comparisons, and actionable insights—available in both PDF and spreadsheet formats for ease of integration.
Market Scope and Segmentation
– Aspects
– by Therapeutic Area
– Dosage Form
– Type of Immunoglobulin
– End User
– Key Geographical Regions
– Key Market Players
By Region
North America, (U.S., Canada, Mexico), Europe, (France, Germany, Italy, Spain, UK, Russia, Rest of Europe), Asia-Pacific, (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific), LAMEA, (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
This segmentation structure provides a clear framework for understanding market dynamics, segment-specific trends, and growth opportunities.
Read More :- https://www.rootsanalysis.com/reports/intravenous-immunoglobulin-market.html
Technological and Strategic Insights
The report includes a detailed assessment of:
These insights are presented neutrally, supported by empirical evidence and primary research validation.
Historically, immunoglobulins were primarily administered via intramuscular and subcutaneous routes. However, in response to the limitations associated with these methods, developers created intravenous gamma globulin preparations, which have since been employed to address a wide array of clinical conditions.
FDA has till now approved at least 12 human IVIg for treatment of several disorders. It is worth highlighting that Yimmugo, developed by Biotest, is the most recent intravenous immunoglobulin to receive approval in the United Kingdom for the treatment of patients with congenital and acquired immunodeficiencies and for immunomodulation. This approval was announced in September 2023, and it enables future sales growth and provides an important therapeutic option for pediatric and adult patients with these conditions.
The key market drivers for the intravenous immunoglobulin industry include the growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of IVIG treatments, rising use of off-label indications, robust pipeline, government initiatives, enhanced purification techniques, and approval of novel IVIG therapies.
The World Health Organization reports that there are currently over 50 distinct Primary Immune Deficiency (PID) conditions such as specific antibody deficiency, X-lined hypo-gamma-globulinemia, and others. PID encompass 176 different types of rare hereditary disorders. The U.S. National Library of Medicine and National Institute of Health estimates that approximately 6 million patients are affected by PID worldwide. Growing incidences of these diseases are expected to boost the demand for immunoglobulin therapies over the forecast period.
The key market restraints for the intravenous immunoglobulin market include stringent government regulations, high risk of side effects, and high cost of IVIG therapy.
Immunoglobulin infusions are typically administered every 3 to 4 weeks, with around 12-16 sessions per year. The estimated cost of IVIG is approximately USD 73.89 per gram, with a total cost of up to USD 10,000 depending on the severity of the illness. Immunoglobulin replacement treatments are long-term therapies that typically last for 6 months. According to the ABIM Foundation, the expense of IgG treatment therapy exceeds USD 30,000 per year. The cost of IVIG treatment varies depending on several factors, such as the indication, duration of treatment, and the patient’s body weight. On average, the reported cost for IVIG treatment in the US is approximately USD 9,720, and if patients undergo 4 to 5 infusions per month, then it would cost them around USD 41,796 per month.
The global intravenous immunoglobulin market is highly fragmented, with the presence of several international as well as regional players.
Key Market Players
Profiles of prominent companies include:
Each profile highlights:
Regional Insights
Each region is analyzed based on:
Comparative insights across regions enable targeted market entry and expansion strategies.
Report Structure
Customization and Support
For tailored analysis or bespoke reporting needs, please contact our team. We offer customized data sets, region-specific insights, and strategic consultation aligned with your objectives.
About Roots Analysis
Roots Analysis is a global research and consulting powerhouse specializing in Healthcare, Pharmaceutical, Biotech, Semiconductors, Chemicals and ICT industry. With over a decade of experience, they’ve supported more than 750 clients — spanning Fortune 500 companies, innovative startups, academic institutions, VCs, and strategic investors.
Why Use Roots Analysis in era of Artificial Intelligence?
By combining world-class domain expertise, careful data gathering, and dialogue with senior industry experts, Roots Analysis ensures their deliveries are trustworthy, actionable, and aligned with strategic priorities. The value proposition generated on insights generated by Roots Analysis team is unparalleled in the market research industry.
Services Offered:
Roots Analysis offers bespoke consulting services tailored to the unique needs of clients in the life sciences and healthcare sectors.
They specialize in market assessments, tracking industry trends, dynamics, and competitive positioning. These insights help companies fine-tune their product strategies and market-entry plans.
Roots Analysis also delivers expert guidance on partnerships, licensing, and investment opportunities. Their strategic support extends to KOL identification, publication analysis, and regulatory intelligence, making them a valuable partner in business growth and innovation.
With their subscription plans, Roots Analysis provides seamless access to a vast library of market intelligence reports. Subscribers enjoy unlimited downloads in multiple formats.
The service includes on-demand research support—allowing clients to request tailored insights and initiate custom research topics. This ensures that emerging needs are met quickly and effectively.
Each subscription comes with a dedicated account manager and direct access to analysts. Flexible billing options and tiered plans make this service suitable for organizations of all sizes seeking continuous, reliable insights.
Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: [email protected]
Website: https://www.rootsanalysis.com/
© 2025 Crivva - Hosted by Airy Hosting Managed Website Hosting.
